The Introduction succinctly presents the needed background to assess the existing burden of febrile seizures associated with vaccine in earlier surveillance studies. It should also describe the ongoing vaccine safety programs that exist within Western Australia.
Several additional points should be made in the Methods and will be outlined below. 1. What studies were conducted to characterize the vaccines? Did all the lots meet licensing requirements? Were studies done to see if the vaccines were split appropriately? Whole virus vaccine use in children in the 1970s and 80s were also associated with febrile seizures. Could this be explaining the etiology of the seizures?
In the Results, 1. the authors should approximate what percentage of the vaccinated population were included in the assessment of the rate of febrile reactions and febrile seizures in the Perth hospitals after 2010 TIV vaccination. 2. the interpretation of the increased rate of fever associated with the Junior vaccine brand is complex and needs to include whether this is because younger children are receiving the Junior vaccine more commonly, or whether there are inherent differences between the Junior and the regular CSL vaccine. 4. Does the historical comparison of febrile seizures, include only those 9 Perth hospitals? Please clarify.
The Discussion has a number of points that need to be addressed. 1. The authors state that this is the first vaccination program to be suspended of any type in Australia. Was the Wyeth rotavirus vaccination program suspended in Australia? 2. The higher rates of febrile reactions with the Junior brand of vaccine needs to be acknowledged and potential reasons discussed. 3. The statement that "this is unlikely to represent a new, distinct clinical syndrome resulting from a neurotoxic effect of the vaccine? is interesting but what studies have been conducted to date on the vaccine to ensure that is not the case. Again as mentioned above, earlier studies of whole influenza virus administered to children yielded similar patterns of febrile seizures. Do the CSL vaccines associated with fever, have high concentrations of whole influenza virus? 4. Given the fact that the other vaccines are not associated with these febrile reactions, would a reasonable conclusion be that the other vaccines should be used preferentially over the CSL vaccines until the etiology of the problem is identified? This should be acknowledged in the conclusions. Why was the entire program interrupted when only one vaccine type was associated with the reactions? 5. Were these febrile reactions restricted to only children? Were children that were multiply vaccinated actually at more or less risk for febrile reactions? 6. the comment that the vaccine was not "neurotoxic" needs clarification or should be removed. What were the criteria used for that definition? 7. What was the f/u of the kids with seizures -did any require admission? Were there any complex seizures or were there other neurologic manifestations? Were there any identified sequelae?
analyses and data sources to investigate the relationship of 2010 TIV influenza vaccine and seizures, an effort enhanced by the central reporting of this geographic area and a retrospective studies performed both on ED data and a retrospective cohort sample. This information needs to be available to agencies and health authorities advocating influenza vaccine for children, and the authors have done a commendable job in presenting the data clearly and cohesively.
Specific comments: Abstract: Clearly written, well presented overall. However, in the Interpretation section, next to last sentence: it is not clear why these authors comment on continuing vaccination programs in other countries (first sentence of "interpretations") since there is no new or direct data presented in this paper; this sentence should be deleted.
Introduction: Well presented. Another sentence documenting the lack of fevers associated with previous studies of flu vaccine in children would be useful in the 2nd paragraphs. The lack of significant increased rates of fevers, as well as the absence of seizures, in clinical studies supports the passive data of VAERS and the population-based data of VAERS. It is plausible that the seizures could be related to fevers in these children, and flu vaccines in the US have not had any increased rates of even low grade fevers in recent studies in young infants as well as pre-school children. It is also unfortunate that no data on the rates of fever in the CSL vaccine in other years or previous studies is available.
Methods: Would like to clarify that no live-attenuated influenza virus vaccine was utilized in WA. Clear description of ascertainment of rates of febrile convulsions; only item missing was a "backward" check in terms of assessing known cases reported directly to the authorities and verifiying the children were indeed coded accurately with the correct ICD10 code.
Page 9-rates adjusted by a factor of 1.4: can the authors provide estimates later if the factor is not adjusted upwards?
Page 12-Statistical analysis: Appears reasonable. It is not clear how the fever was captured for all patients for the multivariate model, as there is not mention of capturing fever data in patients in this study. If this analysis is utilized, there should be mention in the methods how the temperature data was obtained (by history? Emergency room data? Parental report?) Results: As listed above, report of known temperatures based on measurement in the ED would be useful to report here. What percent of children with "febrile convulsions" had a temperature determined (in an attempt to make sure these were "febrile convulsions"). Figure 1 is very helpful; one comment would be to have the bars with more differential in color so that the different groups could be distinguished in a black and white format. Also, the investigation of diarrhea illness such as rotavirus or norovirus epidemiology during the period that is added in the discussion on page 32 needs to be presented in the methods and results section and not just added into the discussion.
Page 15-historical comparison: can the authors demonstrate that the increased rates of reporting of febrile convulsions in 2010 was not related to increased publicity, ie, can the authors show when the medical and general community were notified of this increased risk in comparison to the reporting of the seizures (as seen in Figure 1? ) Discussion: Again, main points of paper are clearly presented. Page 18, line 32-the point of no evidence of increased rates of childhood infections is important. As stated earlier, this should be presented in methods and results. Can the authors specifically document that no excess of rotavirus (or norovirus) cases were seen in WA during this time period, as rotavirus would be a likely etiology (and easily identified).
Page 18-It is fine in the discussion to discuss implications for northern hemisphere countries-I just don"t think it belongs in the abstract. Conclusion on page 19 is appropriate Minor additional comments I hope will be helpful to make the findings more understandable to an international audience and improve presentation of results and discussion. Introduction page 6 line 12: it would be helpful to give rates and state how much higher the rates of severe disease are compared to a suitable baseline group or compared to outside the flu season. Line 30: It would be useful to assess the literature based on robustness of the methods used to examine safety ie separating out passive surveillance findings from database analytic studies. A sentence or two about the limitations of passive surveillance would be useful (see above).
The authors mention Australia"s reporting of adverse events includes the public reporting directly to the national passive reporting system. How long this public contribution has been collected would help in the interpretation of the time trends in AEFIs presented. Line 20 The recommendations in Australia for dose size, number of doses and timing between doses of TIV by age group should be given. Page 7 line 31: A summary of the methods used here or early in the methods section and the time line would make the paper clearer eg a descriptive analysis of the temporal clustering of febrile convulsions was conducted in ? April 2010 followed by.. Page 7 Methods The paper states that previous seasonal flu vaccine exposure / monovalent H1N1 pandemic flu vaccine exposure was not associated. See below regarding the analysis -if two doses are recommended, did the analysis take this into account i.e. did most febrile seizures occur following first or second dose? Probably most febrile convulsions occurred soon after first dose but this should be stated or analysed. Page 9 line 47 to 51: A very small point: linking of individual records of events to records holding individual records on formulation of vaccine given rather than the term "cross-matching " might be a more specific description of what was done. Could the percentage that were successfully linked and what variables were used for linking also be given?. Page 10 line 8 : The case definition for febrile seizure used and timeframe (eg under 72 hours post vaccination) should be mentioned. How the Brighton collaboration case definition for generalised seizure was used to provide "established diagnostic criteria" is unclear. The Brighton definitions have levels 1, 2,3 for diagnostic certainty (i.e. from "witnessed tonic-clonic activity" to only a "history of unconsciousness"). It does seem unlikely there were enough data to use these Brighton levels in this study. It might be the classification was made more simply based on physician (or parent) report of a febrile seizure. Page 10 line 17: Could details of who the vaccine providers were be added and what the response rate was? Some justification of the inflation factor of 1.4 used or some sort of sensitivity analysis is required. Page 10 line 40: What was the definition of "other febrile reactions"?
It should be made clearer that only the passive reporting system was used for other febrile reactions but for febrile convulsions emergency dept data (EDIS) were additional. It would be useful to also look at the pattern of other febrile reactions in the earlier years. -include the fact that no signal was seen for monovalent pandemic vaccine (PM) •Response from authors: the rate of febrile convulsions (FCs) associated with the monovalent pandemic vaccine produced by CSL Biotherapies, Panvax, was found by TGA to be between 0.08/1000 and 0.17/1000 (the time between vaccination and FC for inclusion in this analysis was not stated) http://www.tga.gov.au/alerts/medicines/atagi-tga-report.htm. This is considerably less than the 3.3 febrile convulsions per 1000 vaccine doses found in our study to be associated with Fluvax or Fluvax Jr (febrile convulsion within 72 hours of vaccination), but higher than the figure found in the Vaccine Safety Datalink (VSD) program of 0.014/1000 (FC within 72 hours -ref. 3 in our paper), or the VSD data cited in the TGA paper cited by the reviewer http://www.tga.gov.au/alerts/medicines/vaccine-overview.htm (FC with 24 hours). The authors feel that this information need not be include in the revised manuscript owing the different methodologies used in these studies, which makes direct comparison problematic, a need to keep within the word limit, and the questionable relevance to our paper.
-discuss the other investigations that were carried out as well as what the final decisions were that were taken (PM).
• The TGA summary concluded that the rate of FCs in WA associated with CSL vaccines was 7/1000 in Western Australia and 5/1000 in other states, although it is unclear in the report precisely what numerators and denominators were used to derive these figures. Reference to the non-WA states is made in the Discussion section of the revised manuscript.
The supporting results from investigations in other countries who also used the vaccine or similar vaccine should be added (PM).
• The only other southern hemisphere country to use CSL Biotherapies TIV in 2010 was New
INTRODUCTION
Should also describe the ongoing vaccine safety programs that exist within Western Australia (KE).
• The wording describing the systems for monitoring adverse events following immunisation (AEFI) in Australia have been modified and are now included in the Introduction.
Another sentence documenting the lack of fevers associated with previous studies of flu vaccine in children would be useful in the 2nd paragraphs. The lack of significant increased rates of fevers, as well as the absence of seizures, in clinical studies supports the passive data of VAERS and the population-based data of VAERS. It is plausible that the seizures could be related to fevers in these children, and flu vaccines in the US have not had any increased rates of even low grade fevers in recent studies in young infants as well as pre-school children. It is also unfortunate that no data on the rates of fever in the CSL vaccine in other years or previous studies is available (JE).
• Reference to fever as a side effect of TIV in children has now been included in the Introduction of the revised manuscript. In fact, a paper does exist that describes the rate of fever in CSL vaccines (22 to 40%, depending if was first, second or 3rd dose of TIV being given).
The several different epidemiological studies conducted could be stated more clearly. eg the limitations of passive surveillance data means a formal examination using an analytical study is required (PM).
• This notion has been included in the revised manuscript.
page 6 line 12: it would be helpful to give rates and state how much higher the rates of severe disease are compared to a suitable baseline group or compared to outside the flu season (PM).
• Reliable figures comparing severity of influenza in children compared to other groups are lacking. A qualitative statement has been added in the Introduction stating that hospitalisation for influenza in children less than two years is comparable to rates in other groups considered to be at higher risk for complications for influenza, including the elderly.
P6 Line 30: It would be useful to assess the literature based on robustness of the methods used to examine safety ie separating out passive surveillance findings from database analytic studies. (PM)
• The difference in robustness of data derived from passive reporting systems versus populationbased studies has been made clearer in the introduction, including a statement of the limitations of data from passive reporting systems.
A sentence or two about the limitations of passive surveillance would be useful. (PM).
• Included in revised manuscript.
The authors mention Australia's reporting of adverse events includes the public reporting directly to the national passive reporting system. How long this public contribution has been collected would help in the interpretation of the time trends in AEFls presented. (PM).
• Public reporting of AEFI has been long-standing. The term "established" has been included in the revised manuscript to describe the reporting system that accepts reports from the public and a reference to this system has been added.
P6 line 20: The recommendations in Australia for dose size, number of doses and timing between doses of TIV by age group should be given (PM).
Page 7 line 31: A summary of the methods used here or early in the methods section and the time line would make the paper clearer eg a descriptive analysis of the temporal clustering of febrile convulsions was conducted in ?April 2010 followed by (PM).
• In the final paragraph of the Introduction, reference is now made to the number of analytical studies described in the manuscript to determine the association between TIV and adverse events in children.
METHODS
What studies were conducted to characterize the vaccines (KE)? Did all the lots meet licensing requirements (KE)? Were studies done to see if the vaccines were split appropriately (KE)? Whole virus vaccine use in children in the 1970s and 80s were also associated with febrile seizures. Could this be explaining the etiology of the seizures (KE)?
• Ours was an epidemiological study to determine the association between TIV and adverse events in children, and was not focussed on determining the cause of the reactions, hence, we have not included this in the Methods or Results. We do, however, now make reference to the scientific studies undertaken by others to determine the biological cause.
Would like to clarify that no live-attenuated influenza virus vaccine was utilized in WA (JE).
• Live-attenuated influenza virus vaccines are not licensed for use in Australia.
Clear description of ascertainment of rates of febrile convulsions; only item missing was a "backward" check in terms of assessing known cases reported directly to the authorities and verifiying the children were indeed coded accurately with the correct ICD10 code (JE).
• Of the 25 cases directly to the authorities, 22 went to EDs of which 18 were EDIS-enrolled hospitals. None of the 18 were coded as R56.0 that we are aware of, but what codes were used are unknown.
• The methods used to ascertain febrile convulsions were the same for the three years for which data was collected. Therefore, we do not feel that there is a risk of introducing a significant a bias and we have not included this analysis in the paper.
Page 7 -The paper states that previous seasonal flu vaccine exposure / monovalent H1N1 pandemic flu vaccine exposure was not associated. See below regarding the analysis -if two doses are recommended, did the analysis take this into account i.e. did most febrile seizures occur following first or second dose? Probably most febrile convulsions occurred soon after first dose but this should be stated or analysed (PM).
• First dose of TIV given in 2010 -57 (90%)
• Second dose of TIV given in 2010 -0 (0%) • Dose number unknown -6 (10%)
• Total -63
• Data collection methods for vaccination history has now been included in the Methods section and the outcomes in the Results section.
Page 9-rates adjusted by a factor of 1.4: can the authors provide estimates later if the factor is not adjusted upwards (JE)?
• If the vaccine dose denominators are not adjusted upwards by the factor of 1.4, then the rates will be 40% higher than as presented in Table 2 . However, this would be an over-estimate of the real rates. The 40% correction is based on cross-checking of the number of returned survey forms from immunization providers (of TIV used in children in 2010), versus the expected number of immunization providers who provide influenza vaccines to children. The latter was determined based on vaccine ordering records. The comparison provided the estimate that 40% of providers of childhood TIV did not return survey forms on the number of TIV doses (by formulation) given. It is believed that the providers who did not return data were likely to use fewer doses than those who did return data. Hence using the 40% correction across all vaccine formulations and batches is likely to "provide the upper limit of the number of doses that might really have been given" (as stated in the Methods), and a relatively conservative estimate of the rate of adverse events.
Page 9 line 47 to 51: A very small point: linking of individual records of events to records holding individual records on formulation of vaccine given rather than the term "cross-matching" might be a more specific description of what was done. Could the percentage that were successfully linked and what variables were used for linking also be given? (PM)
• The term "cross-matched" has been changed to "cross-checked" in the manuscript (note: "crossmatched" was also used on page 11 of 30, line3).
• The variables used to cross-check ACIR were: Surname, first name and DOB.
• 98 out of 99 children who presented to Perth EDIS hospitals and were coded as R56.0 "febrile convulsions" in the study period of 2010 were listed on ACIR.
• Of the 63 cases of febrile convulsions we found to be associated with 2010 TIV in our study, all were listed on ACIR, but only 41 (65%) of the ACIR records had influenza vaccination information included (the information for these 41 cases was corroborated by their primary care giver and/or immunisation provider). The remaining 22 febrile convulsion cases (35%) had their influenza vaccination status ascertained through interviews with their primary care giver and/or immunisation provider (now stated in manuscript).
Page 10 line 8: The case definition for febrile seizure used and timeframe (eg under 72 hours post vaccination) should be mentioned. How the Brighton collaboration case definition for generalised seizure was used to provide "established diagnostic criteria" is unclear. The Brighton definitions have levels 1, 2,3 for diagnostic certainty (i.e. from "witnessed tonic-clonic activity" to only a "history of unconsciousness"). It does seem unlikely there were enough data to use these Brighton levels in this study. It might be the classification was made more simply based on physician (or parent) report of a febrile seizure. (PM) • All R56.0 coded febrile convulsions and any additional febrile convulsions identified through passive reporting were reviewed by one author (CCB) to ensure diagnostic accuracy. A febrile convulsion was defined as any generalised convulsive seizure (level 1,2 or 3 of the Brighton collaboration case definitions) that occurred in a febrile child (temperature on presentation to a health practitioner > 37.5degC). A vaccine associated febrile convulsion was defined as any febrile convulsion that occurred within 72 hours of either the first or subsequent dose of TIV for whom an alternative cause of fever could not be identified either clinically or microbiologically. This information included in revised manuscript.
Page 10 The interpretation of the increased rate of fever associated with the Junior vaccine brand is complex and needs to include whether this is because younger children are receiving the Junior vaccine more commonly, or whether there are inherent differences between the Junior and the regular CSL vaccine (KE).
• The fact that the difference in overall rates (ages <5yrs) of febrile convulsions between Fluvax and Fluvax Jr cannot be explained solely by age differences is shown in the results through the agestratification. Some additional discussion on this observation is now included in the Discussion section of the revised manuscript.
Does the historical comparison of febrile seizures, include only those 9 Perth hospitals? Please clarify (KE).
• Yes. This has now been made clearer in the manuscript.
As listed above, report of known temperatures based on measurement in the ED would be useful to report here. What percent of children with "febrile convulsions" had a temperature determined (in an attempt to make sure these were "febrile convulsions") (JE).
• All 63 cases reported fever, and 58/63 (92%) had a recorded temperature, either by the parent at home, on presentation to ED or in ambulance (see table below ). This information now included in Table 1 in the manuscript.
<38 deg C -1 38-≤39 -19 39-≤40 -25 40-≤41 -8 41-≤42 -3 ≥42 -2 Unknown -5 Figure 1 change the bars to have more differential in color so that the different groups could be distinguished in a black and white format (JE).
• A black and white version of Figure 1 has been prepared (attached).
The investigation of diarrhea illness such as rotavirus or norovirus epidemiology during the period that is added in the discussion on page 32 needs to be presented in the methods and results section and not just added into the discussion (JE).
• This has now been included in the Methods and Results sections of the revised manuscript.
Page 15-historical comparison: can the authors demonstrate that the increased rates of reporting of febrile convulsions in 2010 was not related to increased publicity, ie, can the authors show when the medical and general community were notified of this increased risk in comparison to the reporting of the seizures (as seen in Figure 1 ?) (JE)
• There was no communication to the public or to clinicians prior to the suspension of the program.
This point has been included in the Discussion section of the revised manuscript. • Using the same definitions as described above (i.e. response to reviewer's comment to page 10 line 8), an additional 25 TIV-associated febrile convulsions, not coded as R56.0 were identified. These were identified prospectively through formal vaccine adverse events reports and retrospectively by ED clinicians, primary caregivers and vaccine providers following suspension of the program.
• The text in the Methods has been modified previously and is not required again. • The data from EDIS-enrolled hospitals is derived in near-real-time from diagnoses by ED doctors based on ICD-10 codes as the patient is discharged from the ED. There is no reason to suspect that there would be a systematic difference in this coding over the 3 years of data collection.
A strong temporal relationship is seen. An explanation is required in the introduction of the need to rule out co-incidence and other possible causes and that to assess if there might be a causal relationship requires a formal analytic study. In this case the authors were successfully able to construct an historical cohort study at short notice. (PM) • Reference to the need for formal analytical studies has been included in the Introduction of the revise manuscript.
A multivariate model is mentioned but a few more details on how it was constructed is useful. Were there a priori confounders which were always kept in (eg was prior receipt of other vaccines before the 2010 season)? What was the criteria for retaining other factors in the model? What was in the final model, what was the OR and 95 % for younger age and was this independent of vaccine formulation? (PM)
• The model was created to see if vaccine brand was still associated with "fever" or "significant febrile adverse event" (defined as measured fever > 38.90 and/or rigors and/or convulsions) when simultaneously controlling for three potential a priori confounders: age, prior TIV, prior PANVAX (monovalent pandemic vaccine).
• Model set-up: Clinical outcome (Fever or Sig AEFI) as a yes/no = (age in days) + (Prior Seasonal TIV) + (Prior PANVAX) + (Vaccine Brand)
• In all the models, receiving CSL brand TIV in 2010 (any CSL vaccine, or just Fluvax, or just Fluvax Junior) remains significantly associated with reporting "fever" or "significant febrile adverse event".
